Targeting SLC7A11 with sorafenib sensitizes stereotactic body radiotherapy in colorectal cancer liver metastasis
Drug Resistance Updates · 2025-07 · 81 · 101250
DOI: 10.1016/j.drup.2025.101250 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Drug Resistance Updates, 2025-07. Verfasst von Jiashuai He und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China. Hauptthemen laut MEDLINE: Sorafenib, Colorectal Neoplasms, Liver Neoplasms, Amino Acid Transport System y+. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Guangzhou Municipal Science and Technology Program key projects, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
Colorectal cancer (CRC) with hepatic metastasis is associated with poor prognosis. Stereotactic body radiotherapy (SBRT) can provide local control for unresectable hepatic metastases of patients with CRC. However, the mechanisms of responsiveness to SBRT in metastatic CRC (mCRC) remain unclear. We aimed to identify a strategy to enhance the efficacy of SBRT in patients with CRC liver metastases and its mechanisms. Transcriptomic sequencing of CRC cells exposed to SBRT revealed that SBRT inhibited SLC7A11 expression. Downregulation of SLC7A11 enhanced the sensitivity of CRC cells to SBRT via ferroptosis. SBRT diminished the ability of tumor cells to sustain oxidative stress by impeding the phosphorylation of JNK and c-Jun and the transcription of NRF2. Furthermore, sorafenib, which targets SLC7A11, exerted inhibitory effects on tumor growth when used in combination with SBRT. A phase II clinical trial confirmed that sorafenib combined with SBRT overcame the resistance of liver mCRC with high SLC7A11 expression by inducing ferroptosis. The combination of SBRT and sorafenib demonstrated favorable clinical effects and safety, making it a good option for patients with CRC liver metastasis. STATEMENT OF SIGNIFICANCE: A novel strategy using the combination of SBRT and sorafenib for the treatment of patients with CRC hepatic metastasis was investigated. This strategy overcomes the radiation therapy resistance of mCRC by inhibiting SLC7A11 expression and promoting ferroptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
- Department of Bone and Joint Surgery, The First Affiliated Hospital, Jinan University, Guangzhou, China; Chaoshan Hospital, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
- Department of Ultrasonic Medicine, The second Xiangya Hospital of Central South University, Changsha 414000, China.
- Center of Body Gamma-knife, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
- State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou 510632, China; College of Pharmacy, Jinan University, Guangzhou 510632, China.
- State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou 510632, China; College of Pharmacy, Jinan University, Guangzhou 510632, China; MOE Key Laboratory of Tumor Molecular B…
Förderung
- Guangzhou Municipal Science and Technology Program key projects
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- Jinan University
- Innovative Research Group Project of the National Natural Science Foundation of China
- Guangzhou Municipal Science and Technology Project
Zitieren
APA
He, J., Zhang, Y., Luo, S., Zhao, Z., Mo, T., Guan, H., Li, H., Bian, Z., Zhang, X., Qiu, S., Liu, S., Tang, W., Shi, B., Chen, M., Zhang, D., Pan, Y., & Pan, J. (2025). Targeting SLC7A11 with sorafenib sensitizes stereotactic body radiotherapy in colorectal cancer liver metastasis. Drug Resistance Updates, 81, 101250. https://doi.org/10.1016/j.drup.2025.101250
Vancouver
He J, Zhang Y, Luo S, Zhao Z, Mo T, Guan H, et al. Targeting SLC7A11 with sorafenib sensitizes stereotactic body radiotherapy in colorectal cancer liver metastasis. Drug Resistance Updates. 2025;81:101250. doi:10.1016/j.drup.2025.101250
BibTeX
@article{He2025,
author = {He, Jiashuai and Zhang, Yiran and Luo, Simin and Zhao, Zhan and Mo, Tianmu and Guan, Hanyang and Li, Haoquan and Bian, Zili and Zhang, Xiangwei and Qiu, Shenghui and Liu, Shijin and Tang, Wang and Shi, Bo and Chen, Minfeng and Zhang, Dongmei and Pan, Yunlong and Pan, Jinghua},
title = {Targeting SLC7A11 with sorafenib sensitizes stereotactic body radiotherapy in colorectal cancer liver metastasis},
journal = {Drug Resistance Updates},
year = {2025},
volume = {81},
pages = {101250},
doi = {10.1016/j.drup.2025.101250}
}
EUVIMED